MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This contractor does not cover any current molecular biomarker tests for risk stratification of cutaneous squamous cell carcinoma (cSCC). No covered indications, documentation requirements, or frequency limits are specified in the policy.

"All current molecular biomarker tests used to risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are non-covered by this contractor."

Sign up to see full coverage criteria, indications, and limitations.